IL-3 Receptor α (IL-3Rα): CD123
• Low affinity ligand binding subunit of IL-3R
• Binds IL-3 and heterodimerizes with common β subunit of GM-IL-5-IL-3 receptor complex to induce proliferative and anti-apoptotic signaling • Differentially overexpressed in 93% of AML patients • CD123 is expressed on AML LSC • Correlation between CD123+ cells frequency and prognosis Jordan, et al. Leukemia. 2000 Oct; 14(10):1777-84; Jin, et al. Cell Stem Cell 2009 Jul 2; 5(1):31-42; Munoz, et al. Haematologica 2001 Dec; 86(12):1261-9; O'Brien and Rizzieri Cancer Invest 2013 May; 31(4):215-20; Testa, et al. Blood. 2002 Oct 15; 100(8):2980-8; Tettamanti, et al. Br J Haematol 2013 May; 161(3):398-401; Vergez, et al. Haematologica 2011 Dec; 96(12):1792-8 Flotetuzumab: CD123 x CD3 Bispecific DART® Protein
• DART bispecific platform Root, et al. Antibodies 2016 , 5, 6 Chichili, et al. Sci Transl Med. 2015 7(289) Flotetuzumab Phase 1 Study objectives 
Flotetuzumab Phase 1 Safety
• Flotetuzumab has demonstrated acceptable tolerability to date
• MTDS @500ng/kg/day 7 day continuous infusion
• DLTs @700ng/kg/day dose included Grade 3 IRR/CRS (2pts) and Grade 3 myalgia (1pt)
• One drug-related CNS AE leading to discontinuation
• Infusion-related reaction/cytokine release syndrome (IRR/CRS)
• Any grade: 36/47 (76.6%)
• Grade 3 in only 6/47 (12.8%)
• Discontinued due to IRR/CRS: 4/47 (8.5%)
• Successful intervention to decrease severity and incidence of CRS:
• Early anti-cytokine therapy (tocilizumab) to limit CRS progression • Two-step LID during week 1 (30ng/kg  100ng/kg  Target dose) • Rapid responses after single cycle of therapy in majority of patients that respond (cycles ≤ 2)
• Anti-leukemic activity observed in 8/14 pts (57%)
• Objective resp. rate (CR/CRi/MLF/PR): 6/14 pts (43%) 
